Genticel presents pipeline development at EUROGIN congress held in Seville, Spain
Posted: 6 February 2015 | Genticel
Genticel announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7…
Genticel (Euronext Paris and Brussels: FR0011790542 – GTCL), a French biotechnology company and leading developer of therapeutic vaccines, today announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7.
The EUROGIN congress gathers scientists, clinicians and gynecologists. It gives an overview of current scientific advances in cervical cancer and other diseases related to Human Papillomavirus (HPV) infection. EUROGIN 2015 will highlight ProCervix, Genticel’s most advanced candidate therapeutic vaccine, through two oral presentations about its continuing clinical development.
ProCervix is designed to induce the elimination of cervical cells infected with HPV 16 and/or HPV 18. Both presentations provide further analysis of ProCervix’s phase 1 data and expand on the rationale that led Genticel to embark on the phase II trial back in 2014. Dr Pierre Van Damme, professor in Vaccinology, Director of the Vaccine and Infectious Disease Institute of the University of Antwerp, Belgium, and investigator in both studies with ProCervix said: “I am very satisfied to see this innovative therapeutic vaccine progressing seamlessly in the ongoing phase II clinical trial.”
Genticel will present a preclinical study on Vaxiclase. The technology platform is ideally adapted for use in early-intervention immunotherapies against multiple infectious or cancerous diseases. Specifically, Genticel will provide the pharmacological proof of concept of simultaneous delivery of multiple antigens of several oncogenic HPV types using the Vaxiclase technology. This is a necessary step in establishing the full preclinical proof of concept for Multivalent HPV, Genticel’s second therapeutic vaccine candidate targeting six oncogenic HPV strains.
Genticel will also be present on the exhibitor floor at booth 11.
EUROGIN Sessions featuring ProCervix and Vaxiclase
OC 6 – Vaccine 3 (New developments)
05 Feb 2015 | 8.15 – 9.45 | Auditorium 3 | FIBES II
SS 1 – Immunotherapy of HPV-associated diseases
05 Feb 2015 | 14.45 – 16.15 | Auditorium 3 | FIBES II
SS 2 – New challenges facing HPV 16 & 18 infection
05 Feb 2015 | 16.40 – 18.00 | Auditorium 3 | FIBES II